Integrity Technology Group Inc.(688244.SH): Qianxin Venture Capital plans to reduce its shareholding by no more than 3% of the company's shares.
Integrity Technology Group Inc. (688244.SH) announced that Qianxin Venture Capital, due to a need to exit its investment, plans to reduce its holdings of the company's shares through centralized bidding transactions and block trades by a total of no more than 4,528,800 shares, i.e., no more than 3% of the company's total share capital, within 3 months after 15 trading days from the date of disclosure of this announcement.
Integrity Technology Group Inc. (688244.SH) announced that Qianxin Venture Capital, due to a need to exit its investment, plans to reduce its holdings of the company's shares through centralized bidding transactions and block trades by no more than 4.5288 million shares in total, i.e., no more than 3% of the company's total share capital, within 3 months after 15 trading days from the date of disclosure of this announcement.
Related Articles
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
RECOMMEND
